TNF and psoriasis: Deucravacitinib effectively addresses several limitations of traditional psoriasis therapies, such as cyclosporine and TNF inhibitors, which are often associated with systemic immune suppression, an increased risk of opportunistic infections, injection-related challenges, and inconsistent patient adherence.